Explore the reality of schizophrenia by debunking seven myths and offering compassionate insights into this complex mental ...

People with schizophrenia experience impaired contrast perception, affecting their ability to differentiate light intensity ...

Usually described as a splitting or multiple personality disorder, the concept of schizophrenia is not entirely but rather a ...

Boehringer healthcare HCP Illustrative image Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, ...

Using a multi-strain probiotic formulation, researchers conducted a double-blind, randomized, placebo-controlled trial aimed at improving psychiatric and cognitive symptoms, intestinal permeability, ...

While imbalances in dopamine levels in the brain are commonly observed in people with schizophrenia, not all patients with schizophrenia respond to standard antipsychotic drugs that target the ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. | Boehringer Ingelheim’s investigational ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.

Assistant Coroner Lousie Wiltshire’s narrative verdict followed a week-long inquest in Exeter into the death of William ...